USA flag logo/image

An Official Website of the United States Government

Ultrasound-based molecular imaging probe for imaging acute myocardial syndromes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43HL110496
Solicitation Year:
2011
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA10-050
Small Business Information
TARGESON, INC.
850 CARLINS WAY CHARLOTTESVILLE, VA 22903-7666
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Ultrasound-based molecular imaging probe for imaging acute myocardial syndromes
Agency: HHS
Contract: 1R43HL110496-01
Award Amount: $259,721.00
 

Abstract:

DESCRIPTION (provided by applicant): Acute coronary syndromes (ACS) account for an increasing level of healthcare expense although patient morbidity and mortality remain relatively high. Current methods for assessing the extent of cardiac ischemic injury in an acute setting offer limited sensitivity and specificity, which leads to both under- and over-treatment of patients with suspected ACS. In the current project, we propose to develop a novel molecular imaging probe for visualization of recent myocardialischemia using echocardiography. Specifically, we aim to develop a microbubble contrast agent targeted to a molecular marker of recent ischemia. We have identified a novel targeting ligand, and developed a biocompatible coupling chemistry suitable for translation to human use. We will validate ligand conjugation and microbubble stability, and assess the targeting efficacy of the resultant microbubble formulations in vitro and in a mouse model of ischemic memory. Successful completion of these aims will result in a molecular imaging probe that may be used to accurately and rapidly identify patients with recent myocardial ischemia. PUBLIC HEALTH RELEVANCE: Imaging of recent ischemia is a critical unmet need in cardiac care. In the current project, we aim to develop a diagnostic imaging test for detecting recent myocardial ischemia using ultrasound imaging. Success in this project will enable rapid identification of patients who would benefit from myocardium-sparing treatments, and eliminate unnecessaryhospitalizations for patients who have not experienced an ischemic event.

Principal Investigator:

Joshua J. Rychak
877-290-4043
joshua.rychak@targeson.com

Business Contact:

Joshua Rychak
877-290-4043
JOSHUA.RYCHAK@TARGESON.COM
Small Business Information at Submission:

TARGESON, INC.
3550 GENERAL ATOMICS CT MS 02/444 SAN DIEGO, CA 92121-

EIN/Tax ID: 132027135
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No